Publications
65 publications
Funding
4 grantsView NIH portfolio on RePORTER ↗
Active
3 grants- MPIR01CA296285-02Targeting the Epidermal Growth Factor Receptor (EGFR) to Revert Trastuzumab Deruxtecan Resistance in HER2-low Colorectal Cancer.NCI · 2025–2030 · via NIH RePORTER
- MPIR01CA288880-03Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal CancerNCI · 2024–2029 · via NIH RePORTER
- PIR21CA292178-02Targeting Chromosomal Instability in the Evolution of Resistance to Matched Therapies Against Colorectal Cancer to Extend Treatment ResponseNCI · 2025–2027 · via NIH RePORTER
Completed grants (1)
- PIR01CA233736-06Exploiting the distinct genomics and signaling of colorectal cancers to effectively target ERKNCI · 2018–2024 · via NIH RePORTER
News mentions
1 mentionView all WCM news ↗
- Targeting Inflammation May Help Overcome Drug Resistance in Colon CancerMay 21, 2026
According to a new preclinical study by Weill Cornell Medicine and MD Anderson Cancer Center investigators, colorectal tumors often find multiple ways to survive treatment, including additional genetic mutations and activation of cellular pathways typically associated with inflammation and regeneration.